Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
[Summary]Notice Concerning the Formulation of the Medium-Term Management Plan FUSO VISION 2030 Next Stage
[Summary]Notice Concerning the Formulation of the Medium-Term Management Plan FUSO VISION 2030 Next Stage
[Summary]Notice Concerning the Formulation of the Medium-Term Management Plan FUSO VISION 2030 Next Stage
[Summary]Notice Concerning the Formulation of the Medium-Term Management Plan FUSO VISION 2030 Next Stage
[Summary]Notice Concerning the Formulation of the Medium-Term Management Plan FUSO VISION 2030 Next Stage
[Summary]Non-consolidated Financial Results for the Three Months Ended June 30, 2025[Under Japanese GAAP]
[Summary]Non-consolidated Financial Results for the Three Months Ended June 30, 2025[Under Japanese GAAP]
[Summary]Non-consolidated Financial Results for the Three Months Ended June 30, 2025[Under Japanese GAAP]
[Summary]Non-consolidated Financial Results for the Three Months Ended June 30, 2025[Under Japanese GAAP]
Fuso Pharma, Apr-Jun (1Q) Ordinary Profit Decreases by 29%
Notice Concerning Personnel Changes of Executive Officer
Notice Concerning Personnel Changes of Executive Officer
Notice regarding Appeals and Petitions for Acceptance of Appeals
Notice regarding Financial Results Forecast for the Fiscal Year Ending March 31, 2026 (no revision)
Notice Concerning the Conclusion of a Special Overdraft Agreement
(Corrections / Corrections of Numerical Data) Notice Concerning Partial Corrections of the Financial Results for FY2024
Notice regarding the Appeal Court Decision in the Patent Infringement Lawsuit Against Us
[Updated] Non-consolidated Financial Results for the Year Ended March 31, 2025 [Japanese GAAP]
[Summary] Financial Results for the Year
Notice Concerning Change (Additional Appointment) of Representative Director and Appointment of Officer